This page has been archived.
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
Serovar | Number (%) of isolates | Number of isolates by number of antimicrobial classes in the resistance pattern | Number of isolates resistant by antimicrobial class and antimicrobial | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aminoglycosides | β-lactams | Folate pathways inhibitors | Phenicols | Quinolones | Tetracyclines | ||||||||||||||||
1 | 2–3 | 4–5 | 6 | AMK | GEN | KAN | STR | AMP | AMC | CRO | FOX | TIO | SSS | SXT | CHL | CIP | NAL | TET | |||
Schwarzengrund | 30 (50) | 26 | 3 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 4 | 4 | |||||||||
Heidelberg | 4 (6.7) | 3 | 1 | 1 | 1 | 1 | 4 | 4 | 4 | 4 | 4 | 1 | 1 | ||||||||
Senftenberg | 4 (6.7) | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | ||||||||
Hadar | 3 (5) | 1 | 2 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | |||||||||
Worthington | 3 (5) | 3 | 1 | 3 | 3 | 3 | |||||||||||||||
Agona | 2 (3.3) | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | ||||||||
Give | 2 (3.3) | 2 | |||||||||||||||||||
I 4,[5],12:-:- | 2 (3.3) | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | |||||||||||
Ouakam | 2 (3.3) | 2 | 1 | 1 | 1 | 1 | |||||||||||||||
Less common serovars | 8 (13.3) | 2 | 1 | 5 | 2 | 1 | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | |||||||
Total | 60 (100) | 31 | 10 | 14 | 5 | 5 | 5 | 18 | 16 | 16 | 16 | 16 | 16 | 17 | 1 | 1 | 19 |
Serovars represented by less than 2% of isolates were classified as ''Less common serovars''.